Kodiak Sciences (NASDAQ:KOD – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09), Zacks reports.
Kodiak Sciences Stock Down 7.9%
Kodiak Sciences stock traded down $3.43 during mid-day trading on Thursday, reaching $39.98. The company had a trading volume of 814,038 shares, compared to its average volume of 859,325. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -9.59 and a beta of 2.21. The company has a 50 day moving average of $38.78 and a 200-day moving average of $34.80. Kodiak Sciences has a 52 week low of $8.29 and a 52 week high of $47.84.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Headlands Technologies LLC grew its position in Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after buying an additional 5,815 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Kodiak Sciences in the 1st quarter worth approximately $94,000. BNP Paribas Financial Markets lifted its position in shares of Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after acquiring an additional 3,009 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $119,000. Finally, Jane Street Group LLC grew its holdings in shares of Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company’s stock worth $181,000 after purchasing an additional 52,705 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on Kodiak Sciences
Kodiak Sciences Company Profile
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Featured Stories
- Five stocks we like better than Kodiak Sciences
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
